40 results about "CD33" patented technology

Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from a CD33 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders such as acute myeloid leukemia (AML), and relapsed or refractory AML.

The present invention relates to a recombinant antisense oligonucleotide that targets CD33 mRNA and to a method of preparing a substantially pure population of edited eukaryotic cells comprising the steps of i) editing a population of eukaryotic cells by the use of base editors, (ii) treating the same population with antisense oligonucleotides according to the invention to transiently downregulate CD33 and iii) enriching the population of edited eukaryotic cells that is negative for CD33.

Chimeric antigen receptors (CARs) with binding domains derived from a novel suite of human CD33-binding antibodies are described. The CARs include optimized short and intermediate spacer regions. The current disclosure also provides methods of cell expansion / activation processes utilizing IL-2, IL-7, IL-15, and / or IL-21 that improve cellular proliferation and cell lysis of the CARs as described.

This invention describes CD33 antibodies and their antigen-binding fragments, as well as CD33 / vδ2 multispecific antibodies or their antigen-binding fragments. The invention also describes polynucleotides encoding these antibodies, compositions comprising these antibodies, methods for producing these antibodies, and methods for treating or preventing diseases such as hematological cancers using these antibodies.

Disclosed herein are monospecific and multispecific single chain antibodies having specificity for one or more of CD47, PD-L1, HSA, CD33, LAG3, and CD16.

Disclosed herein are monospecific and multispecific single-chain antibodies specific for one or more of CD47, PD-L1, HSA, CD33, LAG3, and CD16.

Disclosed herein are monospecific and multispecific antibodies specific for CD28 and CD3E, and one or more of OX-40, CD40, 4-1BB, HSA, IL-22, PD-L1, CD16, CD47, CD33, LAG3, and EGFR.

Multi-specific immune cell engaging molecules are provided herein. These immune cell engaging molecules bind cancer cells co-expressing CD19 and CD33 while also binding immune cells, allowing the immune cells to recognize and destroy the CD19 and CD33-expressing cancer cells.

The present disclosure provides single- or double-stranded interfering RNA molecules (e.g., siRNA) that target a SiglecS (CD33) gene. The interfering RNA molecules may contain specific patterns of nucleoside modifications and internucleoside linkage modifications, as pharmaceutical compositions including the same. The siRNA molecules may be branched siRNA molecules, such as di-branched, tri-branched, or tetra-branched siRNA molecules. The disclosed siRNA molecules may further feature a 5′ phosphorus stabilizing moiety and / or a hydrophobic moiety. Additionally, the disclosure provides methods for delivering the siRNA molecule of the disclosure to the central nervous system of a subject, such as a subject identified as having a neuroinflammatory disease (e.g., Alzheimer's disease).

The invention provides an antibody composition for detecting immature mononuclear cells and application thereof, the antibody composition for detecting the immature mononuclear cells comprises a first group of antibodies and a second group of antibodies, the first group of antibodies comprises a CD15 antibody, a CD117 antibody, a CD34 antibody, a CD33 antibody, a CD14 antibody, an HLA-DR antibody, a CD13 antibody, a CD38 antibody, a CD64 antibody, a CD19 antibody, a CD56 antibody, a CD7 antibody and a CD45 antibody; and the second group of antibodies comprise an HLA-DR antibody, a CD64 antibody, a CD33 antibody, a CD14 antibody, a CD65 antibody and a CD45 antibody. According to the present invention, the flow cytometry is adopted to detect, and the antibody composition of the first group of antibodies and the second group of antibodies is provided, such that the detection sensitivity and the specificity are improved.

The invention discloses a humanized antibody targeting human CD33 and application thereof, and belongs to the field of biological medicine. The invention provides a monoclonal antibody targeting human CD33, and also provides a composition containing the monoclonal antibody, a multispecific antibody, a chimeric antigen receptor and an antibody conjugate. The monoclonal antibody targeting human CD33 has the characteristics of high affinity and strong killing effect on target cells, and is beneficial to prediction, diagnosis and treatment monitoring of related diseases such as myelogenous leukemia.

Chimeric antigen receptors targeted to CD33 are described together with their use in treating various cancers and in reducing myeloid derived suppressor cells in a patient.

The present disclosure provides improved CD33 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

The disclosure is directed to methods and compositions for treating cancers characterized by cells comprising chimeric antigen receptors (CARs) that bind CD70 and T-cell engaging antibody molecules (TEAMs) that bind CD33, nucleic acid molecules encoding chimeric antigen receptors (CARs) that bind CD70 and / or TEAMs that bind CD33, and compositions and methods related thereto.

We provide a novel anti-CD33 antibody. [Solution] The antibody provided is a pan-conjugate that binds to the C2-set Ig-like domain of CD33 in the presence or absence of the V-set Ig-like domain, or a V-set conjugate that binds to the V-set Ig-like domain of CD33. This antibody provides a novel therapeutic and diagnostic means for CD33-related disorders such as acute myeloid leukemia (AML).

The present invention refers to anti-CD33 specific single domain antibodies, and their use in chimeric antigen receptor cells, mainly T cells, which are of use in the treatment of cancer characterized by an increase in cells expressing CD33, in particular acute myeloid leukemia.

The process of inducing pre-mRNA splicing was disclosed. CD33 Novel antisense oligonucleotides that skip exon 2 in genes and their potential applications in treating neurodegenerative diseases such as Alzheimer's disease.

The present disclosure provides improved CD33 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

This disclosure relates to the use of cells having identifiable surface proteins, which have engineered or naturally occurring mutations but are functional surface proteins, for therapeutic use. The present invention also relates to the use of cells having identifiable CD33 surface protein variants but are functional surface proteins, for therapeutic use, particularly in adoptive cell therapy.

Chimeric antigen receptors (CARs) with binding domains derived from a novel suite of human CD33-binding antibodies are described. The CARs include optimized short and intermediate spacer regions. The current disclosure also provides methods of cell expansion / activation processes utilizing IL-2, IL-7, IL-15, and / or IL-21 that improve cellular proliferation and cell lysis of the CARs as described.

The invention provides compositions and methods for treating cancers and proliferative disorders, including solid tumor cancers and non-myeloid hematological malignancies, using radioconjugates targeting CD33, alone or in combination with one or more radioconjugates targeting other cancer-associated targets such as DR5, 5T4, HER2, HER3, and TROP2, antibody drug conjugates targeting these or other cancer-associated targets, therapeutic antibodies targeting these or other cancer-associated targets, chemotherapy agents and regimens, and immune checkpoint inhibitors.

The present disclosure relates to antibody oligonucleotide conjugates (AOCs) comprising an antisense polynucleotide agent conjugated to a CD33 antibody, methods of use thereof, and methods of producing.

This invention provides CD33-targeting CAR-gdT cells and their application in the treatment of acute myeloid leukemia. Specifically, this invention, through screening, provides CD33-CAR-γδT cells with high transfection efficiency, strong proliferative capacity, and efficient killing of target cells. This invention also provides a method for preparing CD33-CAR-γδT cells and their application in the treatment of acute myeloid leukemia.

Provided are a monoclonal antibody targeting human CD33 and a humanized antibody thereof, and also provided are a composition comprising the antibody, a multispecific antibody, a chimeric antigen receptor, and an antibody conjugate, which facilitate prediction, diagnosis and treatment monitoring of related diseases such as myeloid leukemia.

Here, we developed an epigenome editing strategy to enrich base edited HSPCs by transiently downregulating CD33 expression. CD33 is a surface marker of the myeloid lineage, which is expressed on human HSCs with a high regenerative potential. With this approach, the transient repression will ensure CD33 downregulation only in the timeframe necessary to select and enrich base edited HSPCs. In particular, the present invention relates to a method for editing a population of eukaryotic cells comprising contacting the population of eukaryotic cells with an epigenome editing platform that comprises (a) one or more epigenome-editing enzyme(s), and (b) one or more guide RNA molecule(s) designed for guiding the epigenome-editing enzyme to a target sequence in the gene encoding for the CD33 so as to knock-down the expression of CD33.

CD33 offers a more powerful antagonist. [Solution] A CD33-binding polypeptide and a method for treating, for example, leukemia using the CD33-binding polypeptide are provided. The CD33-binding polypeptide comprises at least one VHH domain.

The invention relates to the technical field of medical detection, in particular to an antibody composition and application. The antibody composition is composed of a CD33 antibody, an HLA-DR antibody, a CD14 antibody, a CD16 antibody and a CD45 antibody. The invention also provides an application of the antibody composition in detection of a peripheral blood mononuclear cell subset. The invention also provides a peripheral blood mononuclear cell subset determination method, which comprises: adding the fluorescein-labeled antibody composition and PBS to a blood sample to be detected, incubating in a dark place, adding the PBS, washing, centrifuging, discarding the supernatant, adding hemolysin, standing in a dark place, adding the PBS, washing, centrifuging, discarding the supernatant, adding the PBS, and detecting the peripheral blood mononuclear cell subset. And performing flow cytometry on a machine for detection. The invention solves the problem that the false positive result is easily caused when the existing antibody combination is used for detecting the mononuclear cell subpopulation.